To verify diagnostic sensitivity and specificity of the novel chemiluminescence method for the detection of the autoantibodies against myeloperoxidase (anti-MPO) and proteinase 3 (anti-PR3). To compare this method with commonly used enzyme linked immunoassays (ELISA) and evaluate the mutual agreement of the methods with indirect immunofluorescence method (IIF).
To assess the utility of chemiluminescent immunoassay (CLIA) as a screening test for ANCA associated vasculitis (AAV) patients.